Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Shuttle Pharmaceuticals, Inc. | s106657_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Shuttle Pharmaceuticals, Inc. | s106657_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Shuttle Pharmaceuticals, Inc. | s106657_ex31-1.htm |
| 10-Q - QUARTERLY REPORT - Shuttle Pharmaceuticals, Inc. | s106657_10q.htm |
Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Shuttle Pharmaceuticals, Inc., a Maryland corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Dritschilo, the Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: June 26, 2017 | SHUTTLE PHARMACEUTICALS, INC. | |
| By: | /s/ Peter Dritschilo | |
| Peter Dritschilo, Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) | ||